The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues. Click here for our view and for more information about how our sector is preparing for Brexit if there's 'no deal'.
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. Find out how pharmaceutical companies are pioneering R&D into the next generation of treatments.
The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines.
Clinical trials are the cornerstone of the research and development process and it is through trials that pharmaceutical companies are able to demonstrate the safety and efficacy of new medicines.
Medicines and vaccines have helped deliver incredible improvements in patient health. This section looks at expenditure on R&D in the UK and around the world.
The UK is a world leader in medical research and innovation, built on the foundation of collaborations between industry and academia throughout Britain.
Discover events for both members and non-members as well as speaking engagements of senior ABPI leadership.
As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.
ABPI Member webinar
The chance to hear a monthly update on the work and arrangements on Brexit and the implications for our business.
Friday 01 November 201912:00 - 13:00
This webinar will be hosted by Elliot Dunster, Head of External Affairs who will be joined by colleagues on specific issues as they arise.
Please note, this webinar is for ABPI member company colleagues only. Please ensure you register with your company email address in to gain access.